NASDAQ:BBOT BridgeBio Oncology Therapeutics Q2 2026 Earnings Report $8.90 +0.01 (+0.11%) As of 09/3/2026 04:00 PM Eastern ProfileEarnings HistoryForecast BridgeBio Oncology Therapeutics EPS ResultsActual EPS-$705.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABridgeBio Oncology Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABridgeBio Oncology Therapeutics Announcement DetailsQuarterQ2 2026Date8/11/2026TimeAfter Market ClosesConference Call DateTuesday, August 11, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) BridgeBio Oncology Therapeutics Earnings HeadlinesBBOT to Participate in Upcoming Investor Healthcare ConferencesSeptember 1 at 4:05 PM | globenewswire.comBridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Average Recommendation of "Moderate Buy" by AnalystsAugust 24, 2026 | americanbankingnews.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25. | Paradigm Press (Ad)BridgeBio Oncology Q2 Loss WidensAugust 12, 2026 | finance.yahoo.comBridgeBio Oncology Therapeutics, Inc.: BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate ProgressAugust 12, 2026 | finanznachrichten.deBridgeBio Oncology Therapeutics, Inc. (BBOT)August 11, 2026 | finance.yahoo.comSee More BridgeBio Oncology Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Oncology Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Oncology Therapeutics and other key companies, straight to your email. Email Address About BridgeBio Oncology TherapeuticsBridgeBio Oncology Therapeutics (NASDAQ:BBOT) (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need. BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development. Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here. Prospective investors and researchers should consult the company’s SEC filings, investor presentations and official disclosures for up-to-date details on its pipeline, management team and strategic priorities.View BridgeBio Oncology Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
